Skip to main content
OpenTrials
Recruiting

NCT Number: NCT03770923

Effect of Some Drugs on Rheumatoid Arithritis Activity

Effect of Some Drugs on Rheumatoid Arithritis Activity.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Sherief Abd-Elsalam

Tanta, 35111, Egypt

Location status: Recruiting

Location contact

Fedaa Kotkata, Msc

CONTACT

About this study

The study aims at evaluating the effect of Some Drugs on Rheumatoid Arithritis Activity.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Rheumatoid arthritis

Exclusion criteria

  • liver or renal disease

Treatment and study plan

Rupatadine

Drug

Rupatadine 10 mg daily

Montelukast

Drug

Montelukast 10 mg daily

Primary outcomes

  1. se level of IL-17

    Time frame: 6 months

    change in level of IL-17

Study contacts

Contact information is provided by the study sponsor or research team.

Sherief Abd-Elsalam, Ph D

CONTACT

[email protected]

00201147773440

Sponsors and collaborators

Lead sponsor

Sherief Abd-Elsalam

Other

Registry information

Official study title

Clinical Study Evaluating the Effect of Histamine 1 Receptor Antagonist and Leukotreine Receptor Antagonist on Patients With Rheumatoid Arithritis

Important dates

Study start
2018
Primary completion
2026
Study completion
2027
First posted
Dec 10, 2018
Registry last updated
Dec 10, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.